Typhoid conjugate vaccine - Bharat BiotechAlternative Names: Typbar-TCV; Typhoid conjugate vaccine (Typbar-TCV) - Bharat Biotech; Typhoid Vi capsular polysaccharide tetanus toxoid protein conjugate vaccine (Typbar-TCV) - BBIL; Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV) - Bharat Biotech; Typhoid Vi polysaccharide-TT conjugate vaccine - Bharat Biotech
Latest Information Update: 17 May 2014
At a glance
- Originator Bharat Biotech
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Typhoid
Most Recent Events
- 15 Apr 2014 Bharat Biotech initiates enrolment in a phase IV trial for Typhoid in India (CTRI2014-04-004532)
- 26 Aug 2013 Launched for Typhoid (prevention) in India (IM); first launch of Typbar-TCV™